Duration of Treatment After Eye Involvement in Giant Cell Arteritis

ERIC LIOZON, GUILLAUME GONDRAN, KIM LY, VÉRONIQUE LOUSTAUD and ELISABETH VIDAL

J Rheumatol 2008;35;1220-1221
http://www.jrheum.org/content/35/6/1220

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Duration of Treatment After Eye Involvement in Giant Cell Arteritis

To the Editor:

We read with great interest the letter by Arashvand, *et al* in a recent issue. These authors investigated whether the presence of eye involvement significantly lengthens the duration of steroid therapy in giant cell arteritis (GCA). The mean duration of treatment in 16 patients with permanent eye involvement (25.69 ± 12.8 months) was significantly longer than in 14 patients without eye involvement (11.2 ± 3.25 months; *p* = 0.0018). This result prompted the authors to conclude that physicians can better estimate the length of treatment period required depending on the presence or absence of eye involvement. In an inception cohort of patients with temporal (giant cell) arteritis, we similarly investigated which of 33 characteristics, including severe eye involvement, were significantly associated with a longer duration of treatment.

From 1976 through 2007, we diagnosed and followed 334 patients with temporal arteritis (255 biopsy-proven cases). Only negative biopsy cases fulfilling at least 3 of the American College of Rheumatology criteria for GCA were regarded as true GCA. Pretreatment clinical, laboratory, and pathological data were recorded prospectively at the time of diagnosis using in each case a specifically designed, comprehensive questionnaire. All the patients but 8 were treated according to the same protocol. Patients without severe ischemic symptoms received prednisone 0.7 mg/kg/day until the patient was symptom-free and the C-reactive protein concentration had fallen below 5 mg/l. The prednisone dose was then planned to be progressively tapered to 0.35 mg/kg within 4 to 6 weeks, then more slowly. Patients with ischemic symptoms or threat to their vision (transient ischemic symptoms, abnormal fundus, or abnormal ophthalmic artery flow on Doppler studies) received prednisone 1 mg/kg initially, often preceded by pulse methylprednisolone, then tapered similarly. Recovery from GCA was defined as no clinical or laboratory relapses for at least 9 months after the cessation of treatment.

In all, 148 patients achieved recovery (mean age at diagnosis 73.2 ± 7 yrs, 93 women). These patients, 12 of whom were treated 1 year or less, were followed for 95 ± 54 months. Using univariate analysis, we compared the initial and followup characteristics of 59 patients who were treated for less than 2 years (mean 17.2 ± 4.7 mo) with those of 89 patients who were treated 2 years or more (mean 37.8 ± 15.9 mo). As depicted in Table 1, patients treated for the short period were indistinguishable from patients who required a longer period of treatment, with regard to all pretreatment characteristics except for a lower frequency of physical changes of temporal arteries (*p* = 0.01). The frequency of severe eye involvement was similar in both groups (8.5% vs 12.4%; *p* = 0.45). The initial prednisone dose was slightly higher in patients treated longer, and fewer patients in this subset received dapsone as a steroid-sparing agent (*p* = 0.018). In addition, short-treatment patients had a significantly lower mean daily dose of prednisone at 3, 6, and 12 months (*p* < 0.001), and had fewer relapses during treatment or after its cessation, than patients who required longer treatment (*p* < 0.001). The proportion of patients initially receiving pulse steroids and the mean number of serious corticosteroid side effects were distributed equally between the 2 groups. As shown in Table 2, a stepwise logistic regression model performed on selected therapeutic and outcome characteristics showed that the mean prednisone dose at 1 year and the mean number of relapses per patient were the only independent outcome predictors of longer treatment duration. Finally, the mean duration of treatment in 16 patients with severe eye involvement (28.3 ± 15.2 mo), including 15 with anterior ischemic optic neuropathy, did not differ from that of patients without this problem (29.9 ± 16.4 mo; *p* = 0.57).

Our study, performed on a large series of unselected patients with GCA treated homogeneously and follow up, did not validate the assumption that eye involvement can reliably predict the length of treatment, and otherwise revealed the finding of abnormal temporal arteries on examination as the only helpful marker of difficult-to-treat GCA. Moreover, the potential role of dapsone as an effective steroid-sparing agent is presented. The discrepancy between our results and those of Arashvand, *et al* can be explained by the different sizes of populations studied, different study designs and therapeutic protocols, and perhaps the patient’s or physician’s fear of occurrence of late fellow-eye involvement after early unilateral vision loss, emphasizing the role of prudent steroid tapering.

In a study from Spain, a strong initial systemic inflammatory response was associated with higher corticosteroid requirements and a longer duration of therapy in patients with GCA. Our results do not confirm this finding. While it may be difficult to predict with accuracy the total duration of treatment of GCA on clinical and laboratory grounds, as well as the results of immunogenetic studies, the slope of prednisone dose-tapering may identify an early stage those patients who are at risk of undertaking a long period of treatment.

ERIC LIOZON, MD; GUILLAUME GONDRAN, MD; KIM LY, MD; VÉRONIQUE LOUSTAUD, MD; ELISABETH VIDAL, MD, Department of Internal Medicine, Dupuytren University Hospital, Limoges, France. Address reprint requests to Dr. E. Liozon, Service de Médecine Interne A, CHRU Dupuytren, 2 rue Martin Luther King, 87042 Limoges, France. E-mail: eric.liozon@unilim.fr

REFERENCES
Correspondence

To the Editor:

We thank Liozon, et al for their useful and expert opinion on our recent article. The mean duration of treatment in our 16 patients with permanent eye involvement was 25.69 ± 12.8 months compared to the mean duration of 28.3 ± 15.2 months in 16 patients with severe eye involvement in the Liozon cohort. The duration of treatment for our patients with permanent eye involvement is therefore no different from the corresponding cases reported by Liozon, et al. The discrepancy between our results can be best explained by different study designs and objectives. Our patients all had temporal artery biopsy-positive giant cell arteritis (GCA), and Liozon, et al


Arashvand, et al reply

To the Editor:

We thank Liozon, et al for their useful and expert opinion on our recent article. The mean duration of treatment in our 16 patients with permanent eye involvement was 25.69 ± 12.8 months compared to the mean duration of 28.3 ± 15.2 months in 16 patients with severe eye involvement in the Liozon cohort. The duration of treatment for our patients with permanent eye involvement is therefore no different from the corresponding cases reported by Loizos, et al. The main difference appears to be that our patients without eye involvement are treated with a much shorter duration of steroid therapy. The discrepancy between our results can be best explained by different study designs and objectives. Our patients all had temporal artery biopsy-positive giant cell arteritis (GCA), and Liozon, et al


Arashvand, et al reply

To the Editor:

We thank Liozon, et al for their useful and expert opinion on our recent article. The mean duration of treatment in our 16 patients with permanent eye involvement was 25.69 ± 12.8 months compared to the mean duration of 28.3 ± 15.2 months in 16 patients with severe eye involvement in the Liozon cohort. The duration of treatment for our patients with permanent eye involvement is therefore no different from the corresponding cases reported by Loizos, et al. The main difference appears to be that our patients without eye involvement are treated with a much shorter duration of steroid therapy. The discrepancy between our results can be best explained by different study designs and objectives. Our patients all had temporal artery biopsy-positive giant cell arteritis (GCA), and Liozon, et al


Table 1. Baseline, therapeutic, and outcome characteristics of patients who recovered from temporal arteritis, by treatment period less or more than 2 years (univariate analysis).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients Treated</th>
<th>Patients Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 2 Years (n = 59)</td>
<td>≥ 2 Years (n = 89)</td>
</tr>
<tr>
<td>Age, yrs</td>
<td>73.7 ± 7.7</td>
<td>72.9 ± 6.7</td>
</tr>
<tr>
<td>Male, %</td>
<td>35.6</td>
<td>38.2</td>
</tr>
<tr>
<td>Comorbid conditions, mean no/patient</td>
<td>0.88 ± 0.85</td>
<td>0.76 ± 0.75</td>
</tr>
<tr>
<td>Concurrent malignancy, %</td>
<td>10.2</td>
<td>6.7</td>
</tr>
<tr>
<td>Positive TAB, %</td>
<td>81.4</td>
<td>88</td>
</tr>
<tr>
<td>Acute onset of GCA, %</td>
<td>40.7</td>
<td>86</td>
</tr>
<tr>
<td>Constitutional symptoms, %</td>
<td>79.3</td>
<td>88</td>
</tr>
<tr>
<td>Systemic symptoms alone, %</td>
<td>13.6</td>
<td>69.3</td>
</tr>
<tr>
<td>Headaches, %</td>
<td>86.4</td>
<td>89</td>
</tr>
<tr>
<td>Occipitalgia, %</td>
<td>42.4</td>
<td>87</td>
</tr>
<tr>
<td>Scalp tenderness, %</td>
<td>50</td>
<td>86</td>
</tr>
<tr>
<td>Jaw claudication, %</td>
<td>27.1</td>
<td>89</td>
</tr>
<tr>
<td>ENT symptoms, mean no/patient</td>
<td>0.81 ± 1.2</td>
<td>1.1 ± 1.13</td>
</tr>
<tr>
<td>Physical changes of temporal arteries, %</td>
<td>42.4</td>
<td>64*</td>
</tr>
<tr>
<td>Upper limb artery involvement, %</td>
<td>15.3</td>
<td>18</td>
</tr>
<tr>
<td>Ischemic symptoms, %</td>
<td>27.6</td>
<td>38.2</td>
</tr>
<tr>
<td>Transient visual ischemic symptoms, %</td>
<td>20.3</td>
<td>24.7</td>
</tr>
<tr>
<td>Permanent visual loss, %</td>
<td>8.5</td>
<td>12.4</td>
</tr>
<tr>
<td>Polymyalgia rheumatica, %</td>
<td>23.7</td>
<td>32.6</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>89.1 ± 35.1</td>
<td>92.7 ± 24</td>
</tr>
<tr>
<td>C-reactive protein, mg/l</td>
<td>97 ± 56</td>
<td>101 ± 67</td>
</tr>
<tr>
<td>Hemoglobin, g/dl</td>
<td>11.6 ± 0.17</td>
<td>11.5 ± 0.16</td>
</tr>
<tr>
<td>Platelet count, g/l</td>
<td>424 ± 142</td>
<td>435 ± 125</td>
</tr>
<tr>
<td>Positive IgG anticardiolipin antibodies, %</td>
<td>24.1</td>
<td>48</td>
</tr>
<tr>
<td>Liver enzyme abnormalities, %</td>
<td>43.1</td>
<td>71</td>
</tr>
<tr>
<td>Initial prednisone dose, mg/kg</td>
<td>0.73 ± 0.14</td>
<td>0.78 ± 0.15**</td>
</tr>
<tr>
<td>Initial use of pulse methylprednisolone, %</td>
<td>18.6</td>
<td>23.6</td>
</tr>
<tr>
<td>Mean prednisone dose at 3 mo</td>
<td>17.9 ± 4.6</td>
<td>22 ± 7.3***</td>
</tr>
<tr>
<td>6 mo</td>
<td>12.3 ± 4.3</td>
<td>16.4 ± 5†</td>
</tr>
<tr>
<td>12 mo</td>
<td>5.3 ± 3.8</td>
<td>10 ± 4.7†</td>
</tr>
<tr>
<td>Use of dapsone as steroid-sparing agent, %</td>
<td>32.2</td>
<td>15.7††</td>
</tr>
<tr>
<td>Mean no. relapses per patient</td>
<td>0.41 ± 0.59</td>
<td>1.02 ± 1†</td>
</tr>
<tr>
<td>Steroid-related complications, mean no/patient</td>
<td>1.14 ± 1.26</td>
<td>1.45 ± 1.43</td>
</tr>
</tbody>
</table>

TAB: temporal artery biopsy; ENT: ear/nose/throat; ESR: erythrocyte sedimentation rate. p values calculated using chi-square test or Mann-Whitney U test, as needed. * p = 0.01; ** p = 0.046; *** p = 0.0004; † p < 0.0001; †† p = 0.018

Table 2. Forward stepwise logistic regression model to demonstrate which of 5 treatment and outcome characteristics were independently associated with treatment duration ≥ 2 years.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean prednisone dose at 3 mo</td>
<td>1.016 (0.879–1.173)</td>
<td>0.83</td>
</tr>
<tr>
<td>6 mo</td>
<td>1.014 (0.835–1.231)</td>
<td>0.89</td>
</tr>
<tr>
<td>12 mo</td>
<td>1.293 (1.041–1.605)</td>
<td>0.02</td>
</tr>
<tr>
<td>Use of dapsone as steroid-sparing agent</td>
<td>0.252 (0.059–1.078)</td>
<td>0.06</td>
</tr>
<tr>
<td>Mean no. relapses per patient</td>
<td>4.916 (2.408–10.472)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>


 Cutaneous Granulomas During Infliximab Therapy for Spondyloarthropathy

To the Editor:

Tumor necrosis factor-α (TNF-α) antagonists are highly effective drugs that have radically improved the functional outcomes and quality of life of many patients with inflammatory diseases. Although TNF-α antagonists are generally well tolerated and safe, the list of reported adverse events is growing steadily. The most common adverse events are infectious diseases including potentially severe infections due to intracellular organisms; allergic reactions including urticaria, rash, and stomatitis; and biological autoimmune disorders. In addition, dermatological events not reported in premarketing clinical trials but seen in everyday rheumatologic and dermatology practice include acne, eczema, psoriasis, vasculitis, bullos lesions, ulcers, skin tumors, xerosis cutis, stasis dermatitis, and edema. We describe a case of cutaneous granuloma and pulmonary symptoms in a patient taking infliximab therapy for spondyloarthropathy (SpA), and we also review the few similar cases reported to date.

A 45-year-old woman presented at our department in 2003 for diffuse back pain of many years’ duration. SpA was diagnosed based on the inflammatory pain pattern, with marked morning stiffness, inflammatory heel pain with an irregular spur on radiograph, good response to nonsteroidal antiinflammatory drug (NSAID) therapy, and history of psoriasis and psoriatic arthritis in the sister and father. B27 typing was negative.

Despite conventional treatment with NSAID and low-dose prednisone (10 mg daily), the disease was still active in August 2004, and infliximab therapy was therefore started. She was in contact with a patient with tuberculosis (TB) in 1986 but did not receive antituberculous treatment, despite a positive intradermal tuberculin test. Although a repeat intradermal tuberculin test was negative in 2004, she was given a 3-month course of anti-tuberculous medications prior to initiation of infliximab, according to national recommendations for the prophylaxis and management of tuberculosis occurring during treatment with anti-TNF-α.

The initial clinical response to infliximab (5 mg/kg) was excellent. However, pruritic, round erythemato-squamous lesions ranging in size from 1 to 5 mm developed over the arms, legs, and face 7 months after initiation of infliximab and persisted over the following months. The clinical diagnosis made by a dermatologist was psoriasis in a patient with no history of cutaneous psoriatic lesions. Topical calcipotriol and betamethasone improved the lesions and were continued despite an incomplete effect.

Fourteen months after infliximab initiation, multiple nodular cutaneous lesions appeared on the left arm and leg. There were about 10 red-brown, round, inflammatory lesions ranging in size from 10 to 20 mm. Simultaneously, deep-vein thrombosis occurred in the left lower leg, with no detectable causal factor, and mild dyspnea with a dry cough developed. Infliximab was discontinued and 2 skin biopsies were performed 1 month apart. Both biopsies showed hypodermitis and noncaseating granulomas composed of epithelioid giant cells surrounded by lymphocytic infiltrates. Findings were normal from standard laboratory tests (renal function, liver enzymes, serum calcium, and 24-h urinary protein). There was no inflammatory syndrome (C-reactive protein < 5 mg/dl and erythrocyte sedimentation rate < 20 mm/h). Tests for antimicrobial antibodies (ANA) were positive at 1/1280, compared to only 1/320 on previous occasions. The level of ANA decreased after clinical recovery and it reached the previous level, 1/320. There were no abnormalities in DNA or complement levels. Standard bacteriological studies and cultures for mycobacteria (M. tuberculosis and atypical Mycobacterium) were performed on the skin biopsy material and on the pulmonary secretions, and remained negative. Computed tomography (CT) of the chest showed a mild interstitial syndrome in both lung bases with ground-glass attenuation and a pseudonodular infiltrate in the left base, as well as a subcarinal lymph node measuring 23 mm in diameter. However, the respiratory symptoms resolved rapidly, prompting a decision to postpone further evaluation by bronchoscopy or lung biopsy. Clinical and CT followup was scheduled.

The skin granulomas resolved shortly after the pulmonary symptoms, 5 months after discontinuation of infliximab. Repeat CT scan showed regression of the bibasal interstitial syndrome and absence of lymphadenopathy. However, an SpA flare developed. After a multidisciplinary discussion, etanercept was started 7 months after discontinuation of infliximab. A marked clinical response was obtained within a few weeks. The inflamma-
tory back pain was well controlled 12 months later, and no additional symptoms developed.

We have described a case of noninfectious granulomatous disease with skin lesions and mild pulmonary involvement during infliximab therapy for SpA. This event was preceded by the development of psoriatic lesions during the treatment.

Noninfectious granulomatous disease in patients undergoing TNF-α antagonist therapy has been rarely reported. Skin granulomas were described in 4 publications12-15 and rheumatoid nodulosis in 36-18. The first case of cutaneous granuloma formation and pulmonary involvement was published in 200213. A 50-year-old woman with rheumatoid arthritis (RA) started experiencing a cough and dyspnea 2 months after initiation of etanercept. The symptoms worsened over the ensuing months. Examination showed scattered pruritic skin lesions on the plantar surfaces of both feet and at the site of superficial scars located on the extremities. Transbronchial and acute skin lesion biopsies showed noncaseating granulomas containing birefringent particles. Etanercept discontinuation and prednisone treatment was followed by a rapid improvement. Development of cutaneous sarcoidosis was reported in 2006 in a 79-year-old patient after 21 months of etanercept therapy for ankylosing spondylitis (AS)15. Red-brown lesions ranging in size from 1 to 1.5 cm developed over the forehead, right eyebrow, and nasolabial area. The skin biopsy showed sarcoidal noncaseating granulomas extending through the entire thickness of the dermis. Bilateral hilar and paratracheal lymphadenopathies were found, further supporting a diagnosis of sarcoidosis. A rapid improvement was obtained after discontinuation of etanercept. Also in 2006, 4 cases of interstitial granulomatous dermatitis associated with TNF-α antagonist therapy were described12. The patients were 2 women and 2 men aged 34 to 65 years (mean 50.2 yrs). Three patients had RA and one had psoriatic arthritis. The drug used was infliximab in 2 patients, etanercept in 1, and adalimumab in 1 patient. The lesions were pruritic or nonpruritic annular nodules, papules, or plaques with elevated borders on the trunk and extremities. Skin biopsies showed diffuse interstitial granulomatous infiltrates. Withdrawal of the medications led to complete resolution of the skin lesions in 3 patients. The lesions persisted in the remaining patient, who continued to take etanercept for severe RA. In 2007, the case was reported of a 39-year-old man who had development of cutaneous granulomatous lesions on the blue pigment area of an old tattoo14. He had been taking etanercept for 1 month for AS. The skin biopsy showed a noncaseating granuloma in the dermis. Topical glucocorticoid therapy with continued etanercept therapy ensured resolution of the lesions. In summary, 7 cases of cutaneous granulomatosis developing during TNF-α antagonist therapy have been reported, 4 in men and 3 in women. The medications were etanercept in 4 cases, infliximab in 2, and adalimumab in 1 case. Patients were aged 39 to 79 years (mean 52.7 yrs). The reason for treatment was RA in 4 patients, AS in 2, and psoriatic arthritis in 1.

Another intriguing feature of our case was the development of 2 rare cutaneous events during infliximab therapy, namely, psoriasis and granulomatosis. We found no similar reports in the literature. A causal link between dermatological or pulmonary disease and exposure to a medication has always been difficult to prove. In our patient, the onset of the skin lesions after initiation of infliximab and their resolution after discontinuation support a causal association with the medication.

Our patient developed granulomatous skin lesions and pulmonary involvement, similarly to a previous case11, although in our patient the pulmonary involvement was mild and bronchoscopy was unnecessary. Withdrawal of infliximab was followed by complete resolution of the symptoms and, interestingly, the introduction of another TNF-α antagonist, etanercept, did not trigger a recurrence.

A few cases of pulmonary granuloma developing during TNF-α antagonist therapy have been reported. They were described as pulmonary granulomatous19 or pulmonary sarcoidosis20-21 on etanercept; necrotizing pulmonary nodules with vasculitis16 or pulmonary granulomatous reaction22,23 on etanercept; and lung necrotizing granulomas24 on adalimumab. Three cases of pulmonary rheumatoid nodulosis25 have been reported in patients taking etanercept. The manifestations resolved after discontinuation of TNF-α antagonist combined, in some cases, with glucocorticoid therapy. In the patient with necrotizing pulmonary nodules and vasculitis16, azathioprine treatment was necessary.

In addition to these cases of granulomatous disease apparently induced by TNF-α antagonist, several instances of granulomatous disease resolving during TNF-α antagonist therapy have been reported26. A number of case reports and small case series described successful treatment of refractory sarcoidosis with infliximab27-29. Preliminary evidence from a randomized controlled trial of infliximab in pulmonary sarcoidosis suggested a modest improvement in functional and radiological manifestations30. Sarcoidosis improved during etanercept therapy in several patients31,32, although the overall results were somewhat disappointing, perhaps reflecting differences in the mechanism of TNF-α blockade compared to infliximab32. Studies of the pathogenesis of tuberculosis support a critical role for TNF-α in immunity and granuloma formation. Further, the 2 forms of TNF-α, soluble and transmembrane, are not equivalent, since mice expressing only transmembrane TNF-α initiated cell migration and granuloma formation, which was effective in controlling acute tuberculosis, but subsequently died from chronic tuberculosis33. Patients treated with anti-TNF-α antibodies (e.g., infliximab), which block both soluble TNF-α and transmembrane TNF-α, might be at greater risk of reactivation of tuberculosis than patients treated with the soluble receptor (etanercept), which blocks soluble TNF-α but binds weakly to transmembrane TNF-α34. Further, binding avidities, clearances, and routes of administration vary across TNF-α antagonists, potentially explaining some of the differences in granuloma formation35. Infliximab and adalimumab have somewhat different mechanisms of action than etanercept, being associated with antibody-mediated cell lysis, in contrast to etanercept. Etanercept, but not infliximab, binds lymphotixin-α and may therefore be more effective in preventing granuloma formation by this mechanism than infliximab. Finally, adalimumab and infliximab seem to inhibit interferon-γ expression (probably indirectly), whereas etanercept does not35. However, these data fail to explain the mechanism by which TNF-α antagonists may induce the development of noninfectious granulomas.

In conclusion, noninfectious granulomatous reaction may be a rare side effect of TNF-α antagonists, with the lung being the most common site of involvement, followed by the skin. Most of the reported cases seem related to etanercept, although our patient had no evidence of granulomatosis one year after switching from infliximab to etanercept. The pathophysiological role of TNF-α and TNF-α antagonists in granuloma formation is unclear. Paradoxically, TNF-α antagonists may be able to induce granuloma formation in some patients and to suppress granulomatous diseases in others.

ANDREA ECONOMOU DUBOSC, MD, Department of Rheumatology; ANNE-MARIE PERROUD, MD, MARTINE BAGOT, MD, PhD, Department of Dermatology; VALÉRIE FARENO, MD, XAVIER CHEVALIER, MD, PhD, Department of Rheumatology; BERNARD MAITRE, MD, PhD, Department of Pneumology; PASCAL CLAUDEPIERRE, MD, Department of Rheumatology, Hopital Henri-Mondor, APHP, Créteil, France. Address reprint requests to Prof. P. Claudepierre, Service de Rhumatologie, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil cedex, France.

REFERENCES


Multiple Autoimmune Diseases in a Young Woman: Tuberculosis and Splenectomy as Possible Triggering Factors? Another Example of the “Mosaic” of Autoimmunity

To the Editor:

The concept of the mosaic of autoimmunity was introduced1 to describe the existence of multiple autoimmune diseases, among other characteristics, in the same individual. It is also well documented that the same clinical example of disturbed autoimmunity may be seen in various family members, e.g., familial antiphospholipid syndrome (APS). By rearranging components of the autoimmune system diverse patterns of autoimmunity become evident2, and the integration of many genetic, hormonal, and environmental factors (e.g., infections) is expressed as overlapping autoimmune diseases. The amelioration of one disease may result in the appearance of another autoimmune disorder, such as women with myasthenia gravis undergoing thymectomy who have an increased risk of developing systemic lupus erythematosus (SLE) or APS3. Another example is of patients undergoing splenectomy for idiopathic thrombocytopenic purpura (ITP) who then have developed autoimmune hepatitis (AIH)4. Coexistent hematological disorders such as thrombotic thrombocytopenic purpura (TTP) as well as other autoimmune diseases have been described not only with SLE, but also with AIH5. We describe a patient with a long history of vitiligo and other autoimmune diseases. The amelioration of one disease may result in the appearance of another autoimmune disorder, such as women with myasthenia gravis undergoing thymectomy who have an increased risk of developing systemic lupus erythematosus (SLE) or APS. Another example is of patients undergoing splenectomy for idiopathic thrombocytopenic purpura (ITP) who then have developed autoimmune hepatitis (AIH). Coexistent hematological disorders such as thrombotic thrombocytopenic purpura (TTP) as well as other autoimmune diseases have been described not only with SLE, but also with AIH. We describe a patient with a long history of vitiligo and ITP who was found to have tuberculosis (TB) of the spleen on histological examination of a surgically removed spleen, and who then developed several other autoimmune diseases including thyroiditis and myasthenia gravis, indeed, a unique series of events in a single patient.
imal weakness of both upper and lower limbs. An electromyogram (EMG) showed evidence of active denervation with fibrillation potentials and positive potentials. Motor unit morphology revealed low amplitude, short duration, and polyphasic potentials indicative of a myopathic process. The compound muscle action potential (CMAP) was normal with no associated abnormalities of the electrophysiological response.

In view of the clinical history, the combination of findings was attributed to steroid-induced myopathy and not to myositis. No muscle biopsy had been performed. As she had also developed non-insulin-dependent diabetes mellitus as a complication of the steroid therapy, a decision was made to taper her from steroids and perform a splenectomy. Following the splenectomy, she showed normalization of the platelet counts. Despite a normal chest radiograph and the absence of any specific symptoms of tuberculous infection, splenic histology revealed several tuberculoid granuloma in the splenic parenchyma. It was considered likely that miliary tuberculosis had arisen because of the prolonged steroid usage. She therefore began a 6-month course of anti-TB therapy.

She remained well post-surgery until 1 year later, when her platelet count again decreased to approximately $34 \times 10^9/l$ and she developed severe menorrhagia. At this stage, she had developed an associated iron deficiency anemia (hemoglobin 9.9 g/dl). She was initially treated symptomatically with iron supplementation for the iron deficiency and epoetinacaproic acid for the bleeding. However, the platelet count continued to fall, with increasing bleeding, particularly from the gums and oral mucosa, which necessitated a blood transfusion and eventually resulted in admission to hospital 3 months later. At this stage her full blood count confirmed a persistent severe thrombocytopenia ($31 \times 10^9/l$) and moderate anemia (Hb 10.2 g/dl). Red cell fragmentation (schistocytes) was seen on the peripheral smear and the level of lactic acid dehydrogenase (LDH) was elevated (282 U/l, normal 96–200 U/l) in keeping with a microangiopathic hemolytic anemia. TTP was diagnosed. She was also in acute renal failure (urea 29 mmol/l, creatinine 690 mmol/l.) Soon after admission, she experienced rapid onset of increasing difficulty breathing. A spiral computerized tomography scan confirmed the presence of multiple pulmonary emboli. She was dialyzed and ventilated and underwent plasma exchange, and responded rapidly, with normalization of the platelet counts and LDH levels and resolution of symptoms within 1 week. An HIV test and autoimmune screen (including antinuclear factor, anti-dsDNA antibodies, and extractable nuclear antigens) were all negative as was a screen for a lupus anticoagulant test and all antiphospholipid antibodies. These were retested on 2 further occasions and were persistently negative. She was extubated after 1 week and discharged. She remained in complete remission, was asymptomatic with normal peripheral counts, off all therapy except for warfarin, which was continued in view of the history of pulmonary emboli.

However, she returned several months later with a history of increasing muscle weakness. Thyroid anti-microsomal antibodies (234.6 IU/ml; normal 0.16–5.61) indicative of Hashimoto’s thyroiditis were highly positive, while thyroid function was normal. She was also noted to have an elevated erythrocyte sedimentation rate (ESR) of 60 mm/h during this admission. She had been unable to walk, climb stairs, and sit on high chairs and also had difficulty swallowing, chewing, and focusing (diplopia) for several months. On examination, she had extensive vitiligo affecting her face, upper limbs, and chest. (Apparently there had been no change in the vitiligo since it initially appeared.) She demonstrated proximal muscle weakness. Her ESR was now elevated to 70 mm/h, platelet counts were elevated to $462 \times 10^9/l$, rheumatoid factors were positive at 246.90 IU/ml. The antinuclear antibodies were negative but serum immunoglobulins were abnormal (260 IU/ml, normal 74–182) with elevation of the gammaglobulin fraction to 20 g/l (normal 6–15). Antibodies to the acetylcholine receptor were highly elevated at 13.40 nmol/l (normal 0.00–0.02). HLA studies revealed a haplotype of A2, B8, DR10. The EMG was normal. A diagnosis of myasthenia gravis was made and 5 days of intravenous immunoglobulin therapy administered (Polygam) in a dose of 28 g/day. Chest radiograph followed by computed tomography scanning (Figures 1A, 1B) revealed the presence of a thymoma measuring 23 × 22 mm, and she underwent thymectomy. Histology showed hyperplasia of the thymus gland. She is now receiving pyridostigmine (Mestinon) therapy and is doing well.

An attempt to “subset” multiple autoimmune syndromes into Types 1–3 was first proposed by Humbert and Dupond in 1988; patients falling into this classification had 3 or more autoimmune diseases. The documentation of our patient clearly shows that this classification is not absolute. Some patients indeed may have autoimmune diseases from several groups. Sowers, et al8 documented disease clusters differing from the Humbert classification, and Anaya, et al8 have also focused admirably on this problem in a recent review. They reviewed multiple autoimmune diseases in the same individual, polyglandular autoimmune syndrome type 1 (Schmidt’s syndrome), as well as familial autoimmune diseases.

It has also been documented in case reports that treatment of one autoimmune disease may result in the emergence of yet another disease such as SLE or an APS9–11. In our patient, splenectomy for treatment of the TTP was associated with the emergence of myasthenia gravis as well as Hashimoto’s thyroiditis. The term “kaleidoscope” of autoimmunity has recently been used to describe the shift of one autoimmune disease to another, and that more than one autoimmune disease may coexist in a single patient or in the same family.8–10.
Vitiligo is a benign cosmetic condition characterized by depigmentation with the loss of melanocytes from the cutaneous epidermis and the demonstration of circulating antibodies and T lymphocytes, which react against melanocyte antigens. It is well known to associate with a diverse number of autoimmune diseases such as autoimmune thyroiditis, insulin–dependent diabetes mellitus, Sjögren’s syndrome, primary biliary cirrhosis, ulcerative colitis, autoimmune polyglandular syndromes, and autoimmune gastritis, characterized by anti-intrinsin and anti-parietal cell antibodies as well as myasthenia gravis, demonstrated in our patient. An increase in vitiligo has also been reported in patients with SLE by Nath, et al, who first reported a susceptibility gene, SLEVI, on chromosome 17p13 in families with vitiligo-related SLE, and their findings have now been confirmed in the report by Jin, et al showing that this same gene characterizes patients with vitiligo and multiple autoimmune diseases, implicating the innate immune system in the pathogenesis of these disorders. Yet a question is raised in this particular patient whether environmental factors may be associated with a change in the risk for development of these diseases.

Autoimmune thyroid disease (AITD) occurs in 5%–10% of patients with myasthenia gravis, and the topic of thyroid autoimmunity with other autoimmune disorders has recently been well reviewed by Szypkravit, et al. It also seems as ifAITD is found in excess in patients with SLE and secondary Sjögren’s syndrome, as well in SLE-unaffected relatives with a diagnosis of primary Sjögren’s syndrome.

Our patient developed TB following prolonged corticosteroid usage, and the association of TB with autoimmunity has been previously postulated. The adjuvant effect of mycobacteria for the development of autoimmunity is also well described, raising the possibility of an infective “trigger” mechanism for the evolution of myasthenia gravis in our patient. We have previously alluded to the induction of diverse autoantibodies following TB infections.

Our case represents another intriguing example of multiple autoimmune diseases occurring in the same patient. However, the haplotype of A2, B8, DR10 did not correspond with the usual one seen in patients with myasthenia gravis, which confers a 10 percent increased risk for the development of these conditions. This has, however, not been confirmed in non-Caucasian populations. Our patient also presented a combination of disturbed humorally-mediated autoimmunity (ITP, autoimmune hemolytic anemia, and myasthenia gravis) as well as cellular-mediated autoimmune disease (vitiligo, Hashimoto’s thyroiditis).

We have previously reported a case of a middle aged, B8/DR3-positive patient who, in addition to having a mild complement deficiency, had then inhaled a chemical (poly-anethol sulfonic acid, a compound with poly-clonal B cell-activating properties) and who, following this exposure, developed 5 different autoimmune diseases. That case, as well as the patient we describe here, supports our theory of the “mosaic of autoimmunity.”

We refer the reader to references 12, 38, 40. This concept supports the hypothesis that not only may a variety of autoimmune diseases be seen in the same family, but that patients with one autoimmune disease have a greater tendency to develop yet another autoimmune disease(s). These patients apparently have a genetic predisposition to develop such diseases, and this may be augmented by hormones (e.g., sex hormones, prolactin) and immune deficiencies, as well as multiple and varied environmental factors.

Ronald A. Asherson, MD, FRCP, FACP, FACP, FACE, Professor of Immunology (Hon), Division of Immunology, School of Pathology, University of the Witwatersrand, Consultant Rheumatologist, The Netcare Rosebank Hospital; Karin Gunter, MB, ChB, MMed, Consultant Haematologist, Floraciliffe, Mayo Clinic; DHarmesh Daya, MB, BCh, FC Rad (SA), Consultant Radiologist, The Netcare Rosebank Hospital, Johannesburg, South Africa; Yehuda Shoenfeld, MD, FRCP (Hon), Head, Department of Medicine B, Center for Autoimmune Diseases (affiliated to Tel-Aviv University), Sheba Medical Center, Tel-Hashomer, Israel.

References

Tuberculosis of the Knee Complicating Seronegative Arthritis

To the Editor:

The diagnosis of tubercular arthritis can be challenging, particularly in the presence of confounding factors such as preexisting arthritis. We describe one such case.
sy, with positive results in 90% of cases. Two consecutive pregnancies made arthroscopy impractical in our patient. The case also illustrates the value of early morning urine examination as a screening tool for tubercular disease in all clinical settings.

The cornerstone of treatment is antituberculous quadruple drug therapy for 2 months followed by dual therapy with rifampicin and isoniazid for a further 4 months or longer, as in our case, depending on the clinical response, particularly in bone disease. Early antimicrobial therapy can result in near-complete resolution and preservation of function.

The World Health Organization reports the global incidence of TB at around 8.8 million and prevalence at 14 million; of this 1%–3% is skeletal disease. A low threshold of suspicion even in the developed world, and especially in the context of immunosuppression and preexisting arthritis, is essential for early identification, appropriate treatment, and limitation of joint damage.

SUBHA ARTHANARI, MRCP(UK), Staff Grade Medical Officer; SIRAJ YUSUF, MBBS, Senior House Officer; MOHAMED NISAR, FRCP(UK), Consultant Rheumatologist, Department of Rheumatology, Queen’s Hospital, Burton Hospital NHS Trust, Burton on Trent DE130RB, United Kingdom. Address reprint requests to Dr. M. Nisar.

E-mail: mohamed.nisar@burtonh-tr.wmids.nhs.uk

REFERENCES

Childhood Stroke as the Presentation of Takayasu’s Arteritis: Diagnostic Delay Can Cause Catastrophic Complications

To the Editor:

Takayasu’s arteritis (TA) is a chronic, potentially progressive, granulomatous inflammation of the aorta and its main branches and it is the most frequent pediatric large-vessel vasculitis. Typical manifestations of TA in adults are diminished or absent pulses associated with claudication, vascular bruits, or hypertension. The incidence in children is 1/million/year. No ethnic differences are known. The diagnosis in children is based on the European League Against Rheumatism (EULAR)/PRES criteria: angiographic abnormalities plus decreased peripheral artery pulse(s) and/or clau-
A 9.5-year-old girl presented to a hospital with a 1-month history of an orbital mass and a drooping left eyelid in April 2005. The computerized tomography (CT) scan revealed an orbital mass. The lesional biopsy revealed granulomatous inflammation with necrosis and giant cells in the arterial adventitia. The blood cell count, erythrocyte sedimentation rate (ESR), chest radiograph, and chest CT were normal. The mass minimized. In March 2006 the girl presented with right-sided facial droop, weakness, and expressive dysphasia. Magnetic resonance imaging (MRI) revealed a nonhemorrhagic infarct of the left middle cerebral artery (MCA) involving caudate nucleus, putamen, globus pallidus, insula, internal capsule, and white matter of the left frontal lobe (Figure 1A). The MRI showed abnormal flow patterns of the left common carotid artery (CCA) and the left MCA. CT angiogram demonstrated an occlusive thrombus in the left CCA (distance 5.5 cm; Figure 1B) and an irregular narrowing of the left MCA. The aortic arch was thickened. Therapy with oral prednisone, methotrexate, and low molecular weight heparin was started.

In April 2006 a right-sided weakness occurred. Four days later she developed an increased weakness of the right arm and leg. MRI revealed a new hypodensity in the left posterior parietal lobe, and volume loss in the region of the previous infarct.

In May 2006, she experienced a brief episode of vertigo, expressive dysphasia, and a right-sided weakness. The cranial MRI showed progressive gliosis in the region of the old infarct.

In June 2006 she had 4 short episodes of right facial droop, right-sided weakness, and expressive dysphasia. MRI showed no changes. Aspirin and gabapentin were added.

In August 2006, 3 episodes of binocular diplopia and unsteadiness occurred. She had decreased pulses in her right arm but no significant drop from her arm to leg. A blood pressure difference of 10 mm Hg between the arms was evident. There were no carotid or abdominal bruits. She had problems with repetitions and a right-sided facial weakness and hemiparesis affecting the arm more than the leg and distal more than proximal. She had a coarse tremor that was present with activity in the right arm and slightly in the right leg. Her deep tendon reflexes were more pronounced on the right side. ESR and C-reactive protein (CRP) were negative. MRI showed new infarcts in the left caudate nucleus and hypothalamus. There was an occlusion of the left CCA from its origin to just inferior to the carotid bulb. The left internal carotid artery was small but was seen filling from the bulb to the region of the ICA terminus, likely in a retrograde fashion via collaterals (Figure 2A). The chest CT revealed a filling defect in the left CCA (Figure 2B).

According to the EULAR/PRES criteria the diagnosis of TA was established. Antiinflammatory treatment with methylprednisolone pulses for 3 days and monthly cyclophosphamide for 6 months was started. Acetylsalicylic acid and heparin were continued.

The diagnosis of childhood-onset TA was established only after a 16-month delay. TA is a treatable disease but can potentially produce disability and death. The tissue biopsy of the orbital mass in our patient revealed perivascular and adventitial inflammation, which can be present in early TA.

The clinical presentation of TA in children is more heterogeneous than in adults. Pediatric patients may present with fever, dyspnea, weight loss, vomiting, and abdominal pain. The most common neurological manifestation in children is severe headache, although dramatic cases of stroke and seizures are also observed. When a child presents with stroke, TA or another vasculitis should be considered, if more common diagnoses such as coarctation, Marfan syndrome, or fibromuscular dysplasia and other vasculitides and tuberculosis have been excluded. Glucocorticoids remain an effective agent for patients with TA. If the disease is relapsing, induction with cyclophosphamide and corticosteroids followed by methotrexate...
is an effective therapeutic option for childhood TA.\textsuperscript{2,16,17} Earlier treatment with a more immunosuppressive therapy might have prevented ongoing strokes. Platelet and coagulation activities are increased in TA. Therefore anticoagulation is indicated. Biologic agents represent a new therapeutic option.\textsuperscript{2,15}

JUERGEN BRUNNER, MD, MSc, Division of Pediatric Rheumatology/Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada, and Pediatric Rheumatology, Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria; DEREK ARMSTRONG, MD, Professor, Diagnostic and Interventional Paediatric Neuroradiology, Department of Diagnostic Imaging, Hospital for Sick Children; BRIAN M. FELDMAN, MD, Professor, Health Policy Management and Evaluation, and Public Health Sciences, University of Toronto, Division of Pediatric Rheumatology, Hospital for Sick Children; RAYFEL SCHNEIDER, MD, Professor; SUSE BENSELER, MD, Division of Pediatric Rheumatology/Neurology, Hospital for Sick Children. Address reprint requests to Dr. J. Brunner, Pediatric Rheumatology, Department of Pediatrics, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: juergen.brunner@uki.at

REFERENCES


Longlasting Remissions After Treatment with Rituximab for Autoimmune Myositis

To the Editor:

In autoimmune myositis, inflammatory involvement of skin and muscles is often refractory to conventional immunosuppressive therapy, and no standardized guidelines exist for the management of progressive and debilitating disease. We describe complete remission of dermatomyositis (DM) after B cell depletion therapy for more than 4 years.

In July 2002, a 54-year-old male patient was admitted to our depart-
ment with a 6-month history of dermatitis on the face, hands, elbows, and ankles, with Gottron’s papules. On examination, marked symmetrical and proximal reduction in muscle strength was evident. Electrophysiologic examination revealed pathologic spontaneous activity of all examined muscle groups; magnetic resonance imaging of both upper legs confirmed severe myositis. Positron-emission tomography showed no evidence of a focal hypermetabolic process; however, significant metabolic activity of proximal arms, shoulders, and neck muscles was consistent with active myositis (Figure 1).

Autoantibody analysis on HEp-2 cells revealed a positive antinuclear antibody (ANA) titer of 1:5120 with a homogeneous, fine-speckled pattern. ELISA revealed positive antibodies against 20S proteasomes, while other myositis related autoantibodies were negative. Consistent with the muscle damage, concentrations of creatinine kinase (1545 U/l, normal range 0–80), myoglobin (1158 µg/l, normal range 0–70), lactate dehydrogenase (505 U/l, normal range 0–240), and transaminases were elevated.

Muscle biopsy from the upper leg revealed focal muscle cell necrosis surrounded by lymphocytes and macrophages, as well as predominantly perivascular infiltrates characteristic for DM.

The clinical and laboratory findings were consistent with severe DM, therefore immunosuppressive treatment was started with high-dose corticosteroids (initially 500 mg methylprednisolone with tapered doses) in combination with intravenous (IV) cyclophosphamide (7 × 1000 mg monthly). However, after an initial improvement of all clinical symptoms, recurrent flares of disease were accompanied by progressive muscle weakness and persistently elevated muscle enzymes [creatine phosphokinase (CPK) repeatedly > 1500 U/l]. After inadequate effect of a last bolus of cyclophosphamide plus a second course of methylprednisolone 500 mg IV in February 2003, the patient was considered as nonresponsive to conventional treatment options. Anti-CD20 therapy with rituximab was administered (3 courses of 1000 mg IV with standard comedication, biweekly), with approval of the local ethics committee, from April to May 2003. The symptoms and laboratory signs of disease activity responded within a few weeks, and longterm remission was achieved for more than 52 months (Figure 2). Immunosuppressive treatment was initially continued with prednisolone monotherapy (≤ 10 mg/day). In September 2004, methotrexate was added (15 mg/wk, escalation to 25 mg/wk in January 2005), leading to reduction of prednisolone to < 10 mg/day. During the observation period, no serious adverse events or infections were observed. B cell (CD19+) counts remained negative until October 2004 (3.8%, 32/µl), and were fully reconstituted only in February 2006 (9%, 91/µl). Interestingly, antiproteasome antibodies were not detectable after June 2004, and ANA titers decreased to 1:640 in November 2004. In October 2007, he presented with progressive generalized myalgias without a significant reduction in muscle strength and recurrent Gottron’s papules. These symptoms were also accompanied by a slight increase in CPK levels for the first time after May 2003, and therefore disease activity of DM was considered to be increasing.

Anti-CD20 therapy with rituximab has been approved for treatment of rheumatoid arthritis (RA) refractory to tumor necrosis factor-α blockers. In addition, evidence for effectiveness of anti-CD20 treatment was provided by several off-label strategies in other autoimmune disorders including systemic vasculitides and connective tissue diseases. In this context, B cell depletion therapy was shown to be an encouraging option also in patients with polymyositis and DM as well as in juvenile DM1–6. However, no data are available from controlled clinical trials of rituximab for treatment of autoimmune myositis.

In RA, the average duration of benefit from a single cycle of treatment with rituximab was 15 months, with a time to retreatment of 20 months7. However, the maximum reported duration of response was 43 months, comparable to our case. Since no clinical or serological predictors for dura-

![Figure 1](image1.png)  
**Figure 1.** Positron-emission tomography revealed strong enhancement of glucose metabolism in the musculature of proximal arms, shoulders, and neck, confirming active myositis. No detection of a focal hypermetabolic process.

![Figure 2](image2.png)  
**Figure 2.** Normalization of CPK levels was accompanied by a complete and longstanding clinical remission over more than 4 years after administration of rituximab (RTX; cumulative dosage 3 g IV).
tion of response to rituximab are known, retreatment is dependent on a subsequent increase of disease activity, as in our patient. We found that long-lasting clinical remission of DM could be achieved after B-cell depletion and continuation of an immunosuppressive treatment, e.g., with corticosteroids in combination with methotrexate. In our patient, low B cell counts were achieved for almost 3 years, and no evidence of disease activity was seen even 1 year after reconstitution of B cells. In RA and other autoimmune disorders, it is well documented that B cell depletion lasts for a period of about 6 months, and B cell reconstitution is typically accompanied by increasing disease activity. Therefore, the unusual B cell recovery in our patient and the continuation of an immunosuppressive regime might explain the longterm remission after a single course of rituximab.

EUGEN FEIST, MD, Department of Rheumatology and Clinical Immunology; THOMAS DÖRNER, MD, Institute of Transfusion Medicine, Charité — Universitätsmedizin Berlin; HELMUT SÖRENSEN, MD, Gesundheitszentrum PrimaVita Berlin; GERD-R. BURMESTER, MD, Department of Rheumatology and Clinical Immunology, Charité — Universitätsmedizin Berlin, Berlin, Germany. Address reprint requests to Dr. E. Feist, Department of Rheumatology and Clinical Immunology, Charité — Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. E-mail: eugen.feist@charite.de

REFERENCES

Book Review

Osteoarthritis: A Companion to Rheumatology


This “Companion to Rheumatology” on osteoarthritis (OA) is a detailed, up-to-date review on the epidemiology, pathogenesis, and radiological, clinical and treatment perspectives of the disorder, written by an international cast of leaders in their fields.

The chapters on pathogenesis provide an excellent discussion on the role of changes in the subchondral bone, chondrocytes, and adipokines (especially leptins) in OA. A section on biochemical markers and discussion on predictors and measurement of disease progression are particularly relevant. The chapter on management is comprehensive and appropriately includes a section on complementary and alternative medicine that is in widespread use among patients. A section on mechanical issues in disease management with discussion on exercises, gait retraining, bracing, and footwear modifications is of particular value for treating physicians. Surgical interventions, however, received only a brief mention.

The book is comprehensive but succinctly written, easy to read, and well referenced and includes black and white but clear illustrations. The authors’ goal of providing a “source of information and ideas for those already involved in osteoarthritis investigation and patient care” has been achieved. This is an excellent text that clearly summarizes the current state of knowledge in OA and is recommended reading for all involved in the study and management of the disease.

Veerapong Phumethum, MD, Clinical Fellow in Rheumatology; Peter Lee, MD, FRCP, FRACP, Professor of Medicine, University of Toronto, Mount Sinai Hospital, Toronto, Canada.